Literature DB >> 10503270

Expression of catenins and p120cas in melanocytic nevi and cutaneous melanoma: deficient alpha-catenin expression is associated with melanoma progression.

X D Zhang1, P Hersey.   

Abstract

E-cadherin mediated intercellular adhesion is regulated by a family of cytoplasmic proteins that include alpha-, beta- and gamma-catenin and p120cas. Changes in expression of E-cadherin are believed to be an early event in melanoma development. Recent studies have also drawn attention to the over-expression of beta-catenin and its possible indirect role as an oncogene in melanoma. In view of these studies, we have examined the expression of cytoplasmic proteins immunohistochemically in 13 melanocytic nevi, 34 primary cutaneous melanomas and 20 metastatic melanomas. alpha-, gamma-catenin and p120cas were heterogeneously expressed in melanocytic nevi and melanomas and were frequently absent, whereas beta-catenin expression was observed in all lesions. The pattern of expression of alpha-, beta- and gamma-catenin and p120cas was characterised by cytoplasmic and membranous immunoreactivity of varying intensity. No significant difference was found in expression of these proteins between melanocytic nevi and primary melanoma. In contrast, there was an inverse correlation between alpha-catenin expression and tumor thickness and alpha-catenin was more frequently expressed in radial compared to vertical growth phase in primary melanoma. Loss of alpha-catenin expression was observed in ten of 20 metastases compared to six of 34 primaries and the expression was more marked in primaries than in metastases. These results indicated that alterations in alpha-, beta- and gamma-catenin and p120cas expression were common in melanocytic nevi and melanomas, and that loss of alpha-catenin expression was associated with melanoma invasiveness and metastasis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10503270     DOI: 10.1080/003130299105052

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  7 in total

1.  Differential expression of CD44(S) and variant isoforms v3, v10 in three-dimensional cultures of mouse melanoma cell lines.

Authors:  Anjali Shiras; Arti Bhosale; Anjali Patekar; Varsha Shepal; Padma Shastry
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

2.  Divergent roles of p120-catenin isoforms linked to altered cell viability, proliferation, and invasiveness in carcinogen-induced rat skin tumors.

Authors:  Rong Wang; Ying-Shiuan Chen; Wan-Mohaiza Dashwood; Qingjie Li; Christiane V Löhr; Kay Fischer; Emily Ho; David E Williams; Roderick H Dashwood
Journal:  Mol Carcinog       Date:  2017-03-06       Impact factor: 4.784

3.  Analysis of beta-catenin mutations and alpha-, beta-, and gamma-catenin expression in normal and neoplastic human pituitary tissues.

Authors:  V Tziortzioti; K H Ruebel; T Kuroki; L Jin; B W Scheithauer; R V Lloyd
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

4.  Abnormal beta-catenin gene expression with invasiveness of primary hepatocellular carcinoma in China.

Authors:  J Cui; X D Zhou; Y K Liu; Z Y Tang; M H Zile
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

5.  Biomarkers: the useful and the not so useful--an assessment of molecular prognostic markers for cutaneous melanoma.

Authors:  Bonnie E Gould Rothberg; David L Rimm
Journal:  J Invest Dermatol       Date:  2010-06-17       Impact factor: 8.551

Review 6.  Bench to bedside and back again: molecular mechanisms of alpha-catenin function and roles in tumorigenesis.

Authors:  Jacqueline M Benjamin; W James Nelson
Journal:  Semin Cancer Biol       Date:  2007-09-04       Impact factor: 15.707

7.  Prognostic significance of cadherin-based adhesion molecules in cutaneous malignant melanoma.

Authors:  Gretchen M Kreizenbeck; Aaron J Berger; Antonio Subtil; David L Rimm; Bonnie E Gould Rothberg
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-04       Impact factor: 4.254

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.